The historical rank and industry rank for Bod Science's Gross Margin % or its related term are showing as below:
ASX:BOD'
s Gross Margin % Range Over the Past 10 Years
Min: 14.54 Med: 35.37 Max: 46.42
Current: 22.76
During the past 9 years, the highestGross Margin % of Bod Science was 46.42%. The lowest was 14.54%. And the median was 35.37%.
ASX:BOD's Gross Margin % is not ranked
in the Drug Manufacturers industry.
Industry Median: 48.44
vs ASX:BOD: 22.76
Bod Science had a gross margin of 15.38% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bod Science was 0.20% per year.
Bod Science (ASX:BOD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bod Science had a gross margin of 15.38% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bod Science Gross Margin % Related Terms
Bod Science Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bod Science's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bod Science Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bod Science's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bod Science's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bod Science (ASX:BOD) has a Gross Margin % of 15.38% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bod Science and its competitors. This is 57% below median its historical median of 35.37. Over the past decade, Bod Science's Gross Margin % has ranged from 14.54 to 46.42.
Is Bod Science's Gross Margin % too high?
Bod Science's current Gross Margin % of 15.38% is 57% below median its 10-year median of 35.37. Over the past 10 years, this metric has ranged from a low of 14.54 to a high of 46.42. The Drug Manufacturers industry median Gross Margin % is 48.44. Bod Science's value of 15.38% is 68.2% below this industry median. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's Gross Margin % compare to ZTS?
Bod Science's Gross Margin % of 15.38% can be compared against companies in the Drug Manufacturers industry. The industry median Gross Margin % is 48.44. Bod Science's value of 15.38% is 68.2% below this benchmark. Historically, Bod Science's own Gross Margin % has ranged from 14.54 to 46.42 over the past decade. While the company's 10-year median is 35.37 vs. the industry median of 48.44, Bod Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bod Science's current Gross Margin % of 15.38% is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current Gross Margin % is 15.38%, which is 57% below median its own 10-year median of 35.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current Gross Margin % of 15.38%. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current Gross Margin % is 15.38%, which is 57% below median its 10-year median of 35.37 and 68.2% below the Drug Manufacturers industry median of 48.44. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current Gross Margin % is 15.38% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bod Science (ASX:BOD) Overvalued in 2026?
Based on GuruFocus' analysis, Bod Science stock appears to be undervalued.
The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.
Key valuation signals for ASX:BOD:
Gross Margin %: 15.38% (57% below median its 10-year median of 35.37)
GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
Industry Position: 68.2% below the Drug Manufacturers median
No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score
Get the complete analysis for ASX:BOD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BOD has been successfully added to your 
